Performant Healthcare, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-29. 2 holders' latest filing reports 5% or more of common stock - $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Mathew P. Arens | 16.36% | 12,923,915 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Glazer Capital, LLC | 8.4% | 6,756,934 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| The Vanguard Group | 4.94% | 3,976,003 | SCHEDULE 13G/A, 2025-10-30 | 2025-09-30 |
| Prescott Group Capital Management, L.L.C. | 0% | 0 | SCHEDULE 13D/A, 2025-10-23 | 2025-10-21 |
| Topline Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-08-05 |
Purpose of Transaction (Item 4)
Prescott Group Capital Management, L.L.C.
Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: On October 21, 2025 (the "Closing Date"), Continental Buyer, Inc., a Delaware corporation ("Parent"), completed the previously announced acquisition of Issuer, pursuant to the Agreement and Plan of Merger, dated as of July 31, 2025 (the "Merger Agreement"), by and among the Issuer, Parent and Project Prevail Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on the Closing Date, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Surviving Corporation"). At the effective time of the Merger (the "Effective Time"), each share of Common Stock issued and outstanding immediately prior to the Effective Time (other than any Common Stock held by (i) the Issuer as treasury stock or held directly by Parent or Merger Sub (or any direct or indirect wholly owned subsidiaries of the Issuer, Parent, or Merger Sub) or (ii) stockholders who have not voted in favor of, or consented in writing to, the adoption and approval of the Merger Agreement, and who are entitled to and have properly demanded appraisal of such Common Stock in accordance with Section 262 of the DGCL) was cancelled and converted into the right to receive an amount in cash, without interest, equal to $7.75. The description contained in this Item 4 of the Merger and the …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-10-23; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 5% | SCHEDULE 13G |
| 2025-08-14 | Mathew P. Arens | 16.36% | SCHEDULE 13G/A |
| 2025-08-21 | Glazer Capital, LLC | 5.82% | SCHEDULE 13G |
| 2025-10-23 | Prescott Group Capital Management, L.L.C. | 0% | SCHEDULE 13D/A |
| 2025-10-30 | The Vanguard Group | 4.94% | SCHEDULE 13G/A |
| 2025-11-13 | Glazer Capital, LLC | 8.4% | SCHEDULE 13G/A |
| 2025-11-14 | Topline Capital Management, LLC | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Performant Healthcare, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.